+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Enanta Pharmaceuticals Inc - logo

Enanta Pharmaceuticals is a biotechnology company that focuses on small molecule drugs for viral infections and liver diseases. Enanta’s research is currently focused on the following disease targets: Hepatitis B Virus (HBV), Non-alcoholic Steatohepatitis (NASH)/PBC and Respiratory Syncytial Virus (RSV). The company has a collaborative development and license agreement with AbbVie to develop and commercialize HCV NS3 and NS3/4A protease inhibitors. Enanta was founded in 1995 and is headquartered in Watertown, Massachusetts.

Hepatitis Drugs Global Market Report 2024 - Product Thumbnail Image

Hepatitis Drugs Global Market Report 2024

  • Report
  • January 2024
  • 200 Pages
  • Global
From
Chronic Hepatitis B Virus Infection - Pipeline Insight, 2024 - Product Thumbnail Image

Chronic Hepatitis B Virus Infection - Pipeline Insight, 2024

  • Clinical Trials
  • April 2024
  • 200 Pages
  • Global
From
Hepatitis B Virus Infection - Pipeline Insight, 2024 - Product Thumbnail Image

Hepatitis B Virus Infection - Pipeline Insight, 2024

  • Drug Pipelines
  • April 2024
  • 180 Pages
  • Global
From
Non-Structural Protein 5 Inhibitor - Pipeline Insight, 2024 - Product Thumbnail Image

Non-Structural Protein 5 Inhibitor - Pipeline Insight, 2024

  • Clinical Trials
  • January 2024
  • 90 Pages
  • Global
From
Vancomycin - Global Strategic Business Report - Product Thumbnail Image

Vancomycin - Global Strategic Business Report

  • Report
  • November 2024
  • 78 Pages
  • Global
From
From
From
From
Respiratory Syncytial Virus (RSV) - Pipeline Insight, 2024 - Product Thumbnail Image

Respiratory Syncytial Virus (RSV) - Pipeline Insight, 2024

  • Clinical Trials
  • November 2024
  • 180 Pages
  • Global
From
NASH Treatment & Therapeutics Market Report 2023-2033 - Product Thumbnail Image

NASH Treatment & Therapeutics Market Report 2023-2033

  • Report
  • July 2023
  • 224 Pages
  • Global
From
From
From
Non-Alcoholic Steatohepatitis (NASH) - Pipeline Insight, 2024 - Product Thumbnail Image

Non-Alcoholic Steatohepatitis (NASH) - Pipeline Insight, 2024

  • Clinical Trials
  • April 2024
  • 240 Pages
  • Global
From
Non-Alcoholic Steatohepatitis (NASH) Global Market Report 2024 - Product Thumbnail Image

Non-Alcoholic Steatohepatitis (NASH) Global Market Report 2024

  • Report
  • February 2024
  • 175 Pages
  • Global
From
Loading Indicator